The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial.
Adult
Anti-Bacterial Agents
/ administration & dosage
Antipsychotic Agents
/ administration & dosage
Cognition
Double-Blind Method
Female
Humans
Male
Middle Aged
Minocycline
/ administration & dosage
Psychiatric Status Rating Scales
Psychotic Disorders
/ drug therapy
Schizophrenia
/ drug therapy
Schizophrenic Psychology
Treatment Outcome
Journal
Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
16
08
2018
revised:
22
10
2018
accepted:
23
10
2018
pubmed:
21
11
2018
medline:
18
6
2020
entrez:
21
11
2018
Statut:
ppublish
Résumé
Studies have hypothesized that immunological abnormalities might contribute to schizophrenia, and basic science studies, as well as several clinical trials suggest that minocycline could be efficacious in ameliorating both positive and negative symptoms of schizophrenia. In this study we examined the effect of minocycline on schizophrenia in a large randomized controlled trial. We performed a 16-week, multi-center, double-blind, randomized, placebo-controlled study on 200 subjects with schizophrenia or schizoaffective disorder randomized to receive either minocycline (200 mg/day, n = 100), or placebo (n = 100) as an add-on to anti-psychotic treatment. The primary outcome measure was the PANSS total score. Mixed models for repeated measures showed no significant difference between minocycline and placebo for total PANSS (p = 0.862), PANSS subscales, CGI or BACS. Minocycline did not improve symptoms or cognition in schizophrenia.
Sections du résumé
BACKGROUND
Studies have hypothesized that immunological abnormalities might contribute to schizophrenia, and basic science studies, as well as several clinical trials suggest that minocycline could be efficacious in ameliorating both positive and negative symptoms of schizophrenia. In this study we examined the effect of minocycline on schizophrenia in a large randomized controlled trial.
METHODS
We performed a 16-week, multi-center, double-blind, randomized, placebo-controlled study on 200 subjects with schizophrenia or schizoaffective disorder randomized to receive either minocycline (200 mg/day, n = 100), or placebo (n = 100) as an add-on to anti-psychotic treatment. The primary outcome measure was the PANSS total score.
RESULTS
Mixed models for repeated measures showed no significant difference between minocycline and placebo for total PANSS (p = 0.862), PANSS subscales, CGI or BACS.
CONCLUSIONS
Minocycline did not improve symptoms or cognition in schizophrenia.
Identifiants
pubmed: 30455075
pii: S0920-9964(18)30625-X
doi: 10.1016/j.schres.2018.10.023
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antipsychotic Agents
0
Minocycline
FYY3R43WGO
Banques de données
EudraCT
['2010-023982-23']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-332Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.